<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887132</url>
  </required_header>
  <id_info>
    <org_study_id>130164</org_study_id>
    <secondary_id>13-M-0164</secondary_id>
    <nct_id>NCT01887132</nct_id>
  </id_info>
  <brief_title>A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism</brief_title>
  <official_title>A Randomized Controlled Trial of Donepezil for REM Enhancement and Behavioral Change in Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Some children with autism spectrum disorders (ASD) do not have normal sleep cycles. Some of
      these children spend very little time in the rapid eye movement (REM) stage of sleep. Some
      studies suggest that less time in REM sleep can be associated with learning and behavior
      problems. Donepezil is a medication used to treat Alzheimer s disease. Donepezil can increase
      REM sleep in some adults with different disorders. A small study showed that Donepezil can
      also increase REM sleep in children with ASD. Researchers now want to see if Donepezil can
      improve communication skills and social interaction in children with ASD. They also want to
      see if any change in symptoms seems to come from changes in REM sleep.

      Objectives:

      - To see if a medication, Donepezil, can improve the way communication skills and social
      interaction develop in young children with autism spectrum disorders.

      Eligibility:

      - Children 22 to 44 months of age with ASD.

      Design:

        -  Participants will be screened with a blood test, heart tests, and a sleep study. During
           the sleep study, children will sleep in a darkened room for 2 nights with electrodes on
           their body and a tube under their nose. Parents can sleep in the room with their child.
           A technician will monitor the room all night.

        -  Participants will take the study medication once a day.

        -  Treatment will be monitored at visits every 3 months. At each visit the participant will
           take blood tests, heart tests, or behavior tests. Participants will have 2 more sleep
           studies.

        -  Participation will end after 18 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      i. Objective

      The objective of this study is to investigate the efficacy of donepezil to improve the
      developmental trajectory for core behavioral domains specific to autism, namely reciprocal
      social interaction and communication.

      ii. Study population

      90 children with an autism spectrum disorder between the ages of 24 to 50 months will be
      screened via polysomnogram to find 45 with a relative REM deficiency. This group will then be
      divided into two arms of drug versus placebo. Allowing for a 22 % drop out rate we expect 17
      in each group to complete the study. Additionally, we will enroll 16 children with an ASD who
      do not meet criteria for relative REM deficiency in an open label arm to ascertain whether or
      not donepezil is beneficial to behavior in this group.

      iii. Design

      The proposal is for a 6 month treatment trial of 2.5 mg donepezil/placebo/day followed by 12
      months of longitudinal follow-up. The primary study endpoint will be an examination of autism
      core symptoms and sleep architecture after 12 months.

      iv. Outcome measures

      The primary outcome measure will be:

        1. An improvement in the Expressive Language and the Receptive Language subscales of the
           Mullen Scales of Early Learning (MSEL) at 12 months.

           Secondary outcome measures will be:

        2. We will also measure the change in REM sleep parameters after 6, 12 and 18 months in
           relation to improvements in behavioral indices.

           Exploratory Outcome Measures will be:

        3. An improvement in the Expressive Language and the Receptive Language subscales of the
           Mullen Scales at 18 months.

        4. An improvement on the severity scale of the Autism Diagnostic Observation Schedule
           (ADOS) at 6, 12 and 18 months.

        5. An improvement on the Vineland at 3, 6, 12 and 18 months

        6. An exploratory analysis will investigate whether normalization of REM parameters also
           improves other measurements of sleep quality in children with autism.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nonverbal Developmental Quotient (NVDQ)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The Nonverbal Developmental Quotient (NVDQ) was calculated from the Mullen Scales of Early Learning scores by dividing the nonverbal mental age (average of the age equivalent value for the Visual Reception and Fine Motor scores) by the chronological age in months. The NVDQ is normalized to a mean score of 100, which indicates an average normal IQ. Less than 100 is a lower than average IQ. 2 standard deviations below average is considered &quot;impaired&quot; IQ (approximately lower than 70).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>REM Percentage at Baseline, 6, 12 and 18 Months</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>REM percentage is the percentage of sleep spent in REM</description>
  </secondary_outcome>
  <other_outcome>
    <measure>An Exploratory Analysis Will Investigate Whether Normalization of REM Parameters Also Improves Other Measurements of Sleep Quality in Children With Autism.</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mullen Scales at 18 Months</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Autism Diagnostic Observation Schedule (ADOS) at 6, 12 and 18 Months</measure>
    <time_frame>6, 12 and 18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vineland Parent Questionnaire at 3, 6, 12 and 18 Months</measure>
    <time_frame>3, 6, 12 and 18 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Autism Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Open-Label Donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil - Blinded</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <arm_group_label>Open-Label Donepezil</arm_group_label>
    <arm_group_label>Donepezil - Blinded</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Diagnosis of an Autism Spectrum Disorder (DSM-IV diagnoses of autistic disorder
                  or Pervasive Developmental Disorder, Not Otherwise Specified).

               2. Male or Female subjects between the ages of 24 and 50 months.

               3. Language scores (from the Mullen Scales of Early Learning) that are at least 1.5
                  SD lower than the mean.

             5. Each legal guardian must have a level of understanding sufficient to agree to all
             required tests and examinations. Each legal guardian must understand the nature of the
             study.

             6. Each subject must be stable for at least 6 weeks on any medication or therapy
             regimen prior to entry into study and must have no newly (within 6 weeks) recognized
             or intolerable adverse effects from that medicine or therapy. No subjects will be
             asked to discontinue any medication in order to qualify for enrollment but subjects
             taking contraindicated drugs will not qualify for enrollment.

             7. Demonstrated REM% two standard deviations or more below the normative values for
             age for the randomized controlled trial part.

             8. English language is primarily spoken at home.

        EXCLUSION CRITERIA:

          1. Serious, unstable illnesses including gastroenterologic, respiratory, cardiovascular
             endocrinologic, immunologic, or hematologic disease.

          2. Renal or hepatic dysfunction that would interfere with excretion or metabolism of
             donepezil as evidenced by increase above upper limits of normal for BUN/creatinine, or
             two-fold elevation of serum transaminases (ALT/SGPT, AST/SGOT) or gamma glutamate
             (GGT).

          3. Documented history of hypersensitivity or intolerance to donepezil or other piperidine
             derivative.

          4. Subjects must not be taking any medication known to affect REM sleep (or sleep

             architecture in general) or that is contraindicated for co-administration with
             donepezil.

          5. Presence or history of other unstable neurological disorders such as seizure
             disorders,

        metabolic disorders, narcolepsy or movement disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>50 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashura W Buckley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anderson DK, Lord C, Risi S, DiLavore PS, Shulman C, Thurm A, Welch K, Pickles A. Patterns of growth in verbal abilities among children with autism spectrum disorder. J Consult Clin Psychol. 2007 Aug;75(4):594-604.</citation>
    <PMID>17663613</PMID>
  </reference>
  <reference>
    <citation>Anderson DK, Oti RS, Lord C, Welch K. Patterns of growth in adaptive social abilities among children with autism spectrum disorders. J Abnorm Child Psychol. 2009 Oct;37(7):1019-34. doi: 10.1007/s10802-009-9326-0.</citation>
    <PMID>19521762</PMID>
  </reference>
  <reference>
    <citation>Bliwise DL, Carroll JS, Lee KA, Nekich JC, Dement WC. Sleep and &quot;sundowning&quot; in nursing home patients with dementia. Psychiatry Res. 1993 Sep;48(3):277-92. Review.</citation>
    <PMID>8272449</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2013</study_first_submitted>
  <study_first_submitted_qc>June 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2013</study_first_posted>
  <results_first_submitted>August 14, 2017</results_first_submitted>
  <results_first_submitted_qc>September 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2017</results_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep Architecture</keyword>
  <keyword>Autism</keyword>
  <keyword>Language Development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD shared via NIMH repository protocol.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>5 participants signed consent. Only 4 started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open-Label Donepezil</title>
          <description>Donepezil</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open-Label Donepezil</title>
          <description>Donepezil</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Mean age of the participants at screening.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" lower_limit="2.1" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nonverbal Developmental Quotient (NVDQ)</title>
        <description>The Nonverbal Developmental Quotient (NVDQ) was calculated from the Mullen Scales of Early Learning scores by dividing the nonverbal mental age (average of the age equivalent value for the Visual Reception and Fine Motor scores) by the chronological age in months. The NVDQ is normalized to a mean score of 100, which indicates an average normal IQ. Less than 100 is a lower than average IQ. 2 standard deviations below average is considered &quot;impaired&quot; IQ (approximately lower than 70).</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Donepezil</title>
            <description>Donepezil</description>
          </group>
        </group_list>
        <measure>
          <title>Nonverbal Developmental Quotient (NVDQ)</title>
          <description>The Nonverbal Developmental Quotient (NVDQ) was calculated from the Mullen Scales of Early Learning scores by dividing the nonverbal mental age (average of the age equivalent value for the Visual Reception and Fine Motor scores) by the chronological age in months. The NVDQ is normalized to a mean score of 100, which indicates an average normal IQ. Less than 100 is a lower than average IQ. 2 standard deviations below average is considered &quot;impaired&quot; IQ (approximately lower than 70).</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NVDQ for participant 1 at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NVDQ for participant 2 at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NVDQ for participant 3 at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NVDQ for participant 4 at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NVDQ for participant 1 at 12 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NVDQ for participant 2 at 12 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NVDQ for participant 3 at 12 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NVDQ for participant 4 at 12 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>REM Percentage at Baseline, 6, 12 and 18 Months</title>
        <description>REM percentage is the percentage of sleep spent in REM</description>
        <time_frame>Baseline, 6, 12 and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open-Label Donepezil</title>
            <description>Donepezil</description>
          </group>
        </group_list>
        <measure>
          <title>REM Percentage at Baseline, 6, 12 and 18 Months</title>
          <description>REM percentage is the percentage of sleep spent in REM</description>
          <units>percentage of sleep</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>REM percentage, participant 1, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 2, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 3, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 4, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 1, 6 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 2, 6 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 3, 6 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 4, 6 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 1, 12 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 2, 12 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 3, 12 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 4, 12 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 1, 18 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 2, 18 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 3, 18 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM percentage, participant 4, 18 mos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>An Exploratory Analysis Will Investigate Whether Normalization of REM Parameters Also Improves Other Measurements of Sleep Quality in Children With Autism.</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mullen Scales at 18 Months</title>
        <time_frame>18 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Autism Diagnostic Observation Schedule (ADOS) at 6, 12 and 18 Months</title>
        <time_frame>6, 12 and 18 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vineland Parent Questionnaire at 3, 6, 12 and 18 Months</title>
        <time_frame>3, 6, 12 and 18 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open-Label Donepezil</title>
          <description>Donepezil</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated due to lack of recruitment. No conclusions regarding the use of donepezil can be drawn from small sample size data collection.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ashura W Buckley</name_or_title>
      <organization>National Institute of Mental Health (NIMH)</organization>
      <phone>(301) 496-5190</phone>
      <email>shu.buckley@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

